Scholarlink

Purpose <p>Sarcopenia is a skeletal muscle (SKM) condition marked by reduced muscle mass and function and is often observed as a comorbidity with inflammatory conditions.</p> Methods <p>We have developed a defined in vitro functional model to study sarcopenia by incubating human-induced pluripotent stem cell–derived SKM cells with 3&#xa0;nM TNF-alpha (TNFα) for 96&#xa0;h. The long-term effects of this treatment were studied for up to 32&#xa0;days in culture. Muscle function was evaluated by measuring myotube width as well as microcantilever contraction amplitude, force, and fatigue index.</p> Results <p>This model revealed the maintenance of a significant reduction in myotube width for 32&#xa0;days after TNF-α treatment; moreover, a decrease in myotube contraction amplitude and an increase in fatigue indices were recorded for 32&#xa0;days. In addition, disease progression and tissue degradation of the sarcopenic conditions were monitored for higher reactive oxygen species production for both acute (day 4) and chronic (day 40) timelines.</p> Conclusion <p>This is the first microphysiological system for sarcopenia evaluation that can be used to evaluate therapeutics. This device can now be combined in a multi-organ microphysiological system to study sarcopenia induced by an inflammatory response from other organs or as a comorbidity in the platform.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Development of a functional sarcopenia model utilizing a microcantilever microphysiological system as a phenotypic disease model

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月22日

查看全文
  • Himanshi Jangir,
  • Leandro H. Gallo,
  • Russell Emmons,
  • James J. Hickman

摘要

Purpose

Sarcopenia is a skeletal muscle (SKM) condition marked by reduced muscle mass and function and is often observed as a comorbidity with inflammatory conditions.

Methods

We have developed a defined in vitro functional model to study sarcopenia by incubating human-induced pluripotent stem cell–derived SKM cells with 3 nM TNF-alpha (TNFα) for 96 h. The long-term effects of this treatment were studied for up to 32 days in culture. Muscle function was evaluated by measuring myotube width as well as microcantilever contraction amplitude, force, and fatigue index.

Results

This model revealed the maintenance of a significant reduction in myotube width for 32 days after TNF-α treatment; moreover, a decrease in myotube contraction amplitude and an increase in fatigue indices were recorded for 32 days. In addition, disease progression and tissue degradation of the sarcopenic conditions were monitored for higher reactive oxygen species production for both acute (day 4) and chronic (day 40) timelines.

Conclusion

This is the first microphysiological system for sarcopenia evaluation that can be used to evaluate therapeutics. This device can now be combined in a multi-organ microphysiological system to study sarcopenia induced by an inflammatory response from other organs or as a comorbidity in the platform.

Graphical Abstract